Omada Health (NASDAQ:OMDA) CFO Steven Cook Sells 15,235 Shares of Stock

Omada Health, Inc. (NASDAQ:OMDA) CFO Steven Cook sold 15,235 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $25.03, for a total transaction of $381,332.05. Following the completion of the sale, the chief financial officer owned 187,209 shares of the company’s stock, valued at $4,685,841.27. This represents a 7.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Omada Health Stock Performance

Shares of NASDAQ OMDA traded down $0.17 during mid-day trading on Wednesday, reaching $23.84. 1,552,408 shares of the company traded hands, compared to its average volume of 1,274,695. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $26.92. The company’s fifty day moving average is $20.61 and its two-hundred day moving average is $16.32. The stock has a market cap of $1.46 billion, a PE ratio of 476.80 and a beta of 1.73.

Omada Health (NASDAQ:OMDA) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.10. The company had revenue of $87.83 million for the quarter, compared to analyst estimates of $80.93 million. Omada Health had a net margin of 1.39% and a return on equity of 2.67%. Research analysts forecast that Omada Health, Inc. will post -0.01 earnings per share for the current year.

Key Headlines Impacting Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Omada’s second-quarter results provided further evidence that revenue growth is translating into profitability. The company reported earnings of $0.08 per share versus a consensus loss of $0.02 and revenue of approximately $87.8 million, well above the $80.9 million analyst estimate. The results support the bullish case for Omada’s digital chronic-care platform and improving financial execution. Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings
• Positive Sentiment: Robert W. Baird raised its price target on OMDA from $15 to $25, reflecting improved expectations following the earnings performance. However, the firm maintained a neutral rating, indicating that much of the near-term upside may already be reflected in the stock price. Benzinga analyst update
• Neutral Sentiment: Analyst sentiment remains broadly favorable, with a reported consensus rating of “Moderate Buy” and an average price target of $25.67. Recent targets range from $24 to $35, but the wide range highlights uncertainty around valuation and future growth.
• Neutral Sentiment: Reported short interest was zero shares, offering no meaningful indication of short-selling pressure or potential short-covering demand.
• Negative Sentiment: CEO Sean Duffy disclosed sales of 8,628 shares at an average price of $21.85 and 12,942 shares at $24.81. The transactions reduced his direct ownership by roughly 5% across the reported sales and may weigh on sentiment, although he still owns more than 411,000 shares.
• Negative Sentiment: At roughly $24 per share, OMDA trades at a very high price-to-earnings ratio near 480, leaving the stock sensitive to disappointment in growth, margins or future earnings. Its recent performance has already placed it well above its 50-day and 200-day moving averages.

Institutional Investors Weigh In On Omada Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OMDA. Raymond James Financial Inc. bought a new position in Omada Health during the second quarter worth about $32,000. Quarry LP bought a new stake in shares of Omada Health in the fourth quarter worth about $29,000. TD Waterhouse Canada Inc. acquired a new stake in shares of Omada Health during the fourth quarter worth about $32,000. Inlight Wealth Management LLC bought a new position in shares of Omada Health during the 4th quarter valued at about $45,000. Finally, Versant Capital Management Inc grew its position in shares of Omada Health by 319.3% in the 2nd quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock valued at $66,000 after purchasing an additional 2,283 shares during the period.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on OMDA shares. Morgan Stanley reiterated an “overweight” rating and issued a $30.00 target price on shares of Omada Health in a research note on Monday, June 22nd. Wall Street Zen raised Omada Health from a “hold” rating to a “buy” rating in a report on Saturday. BMO Capital Markets reissued an “outperform” rating and set a $24.00 price target on shares of Omada Health in a research note on Friday, August 7th. Citigroup reiterated an “outperform” rating on shares of Omada Health in a report on Monday, July 20th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price objective on shares of Omada Health in a research report on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.75.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.